Association of IL-10 Gene Polymorphisms and Human T Lymphotropic Virus Type I-Associated Myelopathy/tropical Spastic Paraparesis in North-East of Iran (Mashhad)

Document Type : Original Article


1 Department of Hematology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Neurology Department, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Rheumatic Diseases Research Centre, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Immunology Research Centre, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Immunology Research Group, Faculty of Life Sciences, The University of Manchester, United Kingdom

6 Inflammation and Inflammatory Disease Research Centre, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


The underlying mechanisms leading to the development of human T-cell lymphotropic virus type I (HTLV-I) associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-I infected individuals are not fully understood. Host genetic factors appear to be involved as risk factors for developing HAM/TSP. We investigated the possible contribution of interleukin-10 (IL-10) as a risk factor to HAM/TSP by comparing frequencies of promoter region single nucleotide polymorphisms in HTLV-I infected Iranian patients who either remained asymptomatic or developed HAM/TSP and asymptomatic HTLV-I carriers. Healthy, uninfected individuals from the same region served as healthy controls. Significant differences were observed in the distribution of IL-10 promoter alleles and genotypes at position -819 and -592 between HAM/TSP patients and healthy controls (P=0.01), and between HTLV-I carriers and healthy controls (P=0.02). The frequency of the low IL-10 producer haplotype (-1082*A, -819*T, -592*A) was significantly associated with HTLV-I carriage or HAM/TSP compared with healthy controls (P=
0.02 and 0.01, respectively). Our results suggest that IL-10 -819*T and -592*A alleles are significant risk factors for developing HTLLV-I infection but do not appear to convey additional risk for developing HAM/TSP


Gessain A, Vernant J, Maurs L, Gout O, Maurs L, Calender A, et al.
Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 326:407-410.
2. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI,
et al
. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 1981; 78:6476.
3. Pawson R, Mufti GJ, Pagliuca A. Management of adult t cell leukaemia/lymphoma. Br J Haematol 1998; 100:453-458.
4. G dT, M K. ??- An HTLV-I/II vaccine: from animal models to clinical trials? D - 9501482. (- 1077-9450 (Print)):T - ppublish.
5. Safai B, Huang J, Boeri E, Farid R, Raafat J, Schutzer P,
et al
. Prevalence of HTLV type I infection in Iran: a serological and genetic study. AIDS Res Hum Retroviruses 1996;12:1185-1190.
6. Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7:266-281.
7. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 1997; 15:15-37.
8. Bangham CRM, Osame M. Cellular immune response to HTLV-I. Oncogene 2005; 24:6035-6046.
9. Kishi S, Saijyo S, Arai M, Karasawa S, Ueda S, Kannagi M
, et al.
Resistance to fas-mediated apoptosis of peripheral T cells in human T lymphocyte virus type I (HTLV-I) transgenic mice with autoimmune arthropathy. J Environ Monit 1997; 186:57.
10 .Miura T, Tanaka H, Making Y, Okamoto K, Iida T, Komura K,
et al
. Human T cell leukemia virus type I-associated myelopathy in a patient with systemic lupus erythematosus. Intern Med 1999; 38:512-515.
11. Lipka K, Tebbe B, Finckh U, Rolfs A. Absence of human T-lymphotrophic virus type I in patients with systemic lupus erythematosus. Clin Exp Dermatol 1996; 21:38-42.
12. Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci 2007; 98:772-778.
13. Boumpas D, Popovic M, Mann D, Balow J, Tsokos G. Type C retroviruses of the human T cell leukemia family are not evident in patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29:185-188.
14. Murphy Jr EL, Ceulaer KD, Williams W, Clark JW, Saxinger C, Gibbs WN,
et al.
Lack of relation between human T-lymphotropic virus type I infection and systemic lupus erythematosus in Jamaica, West Indies. J Acquir Immune Defic Syndr 1988; 1:18.
15. Shah D, Aggarwal A, Bhatnagar A, Kiran R, Wanchu A. Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Free Radic Res 2011; 45:1-9.
16 .Chatterjee M, Kis-Toth K, Thai TH, Terhorst C, Tsokos GC. SLAMF6- driven co-stimulation of human peripheral T cells is defective in SLE T cells. Autoimmunity 2011; 515-48.
17. García-Vallejo F, Domínguez M, Tamayo O. Autoimmunity and molecular mimicry in tropical spastic paraparesis/human T-lymphotropic virus-associated myelopathy. Braz J Med Biol Res 2005; 38:241-250.
18 . Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res Ther 2008; 10:218.
19. Talal N. Immunologic and viral factors in the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 1970; 13:887-894.
20 Phillips P. The role of viruses in systemic lupus erythematosus. Clin Rheum Dis 1975; 1:505-518.
21. Bleich HL, Boro ES, Schwartz RS. Viruses and Systemic Lupus Erythematosus. N Eng Med 1975; 293:132-136.
22 . Pincus T. Studies regarding a possible function for viruses in the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 1982; 25:847-856.
23. Akimoto M, Matsushita K, Suruga Y, Aoki N, Ozaki A, Uozumi K,
et al.
Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus. J Rheumatol 2007; 34:1841.
24 . Koike T, Kagami M, Takabayashi K, Maruyama N, Tomioka H, Yoshida S. Antibodies to human T cell leukemia virus are absent in patients with systemic lupus erythematosus. Arthritis Rheum 1985; 28:841-844.
25. Lolli F, Ernerudh J, Kam-Hansen S, Link H. No association between antibodies to HTLV-I and polymyositis, rheumatoid arthritis and SLE. Scand J Rheumatol 1987; 16:213-215.
26. Kurata A, Katamine S, Fukuda T, Mine M, Ikari N, Kanazawa H,
et al.
Production of a monoclonal antibody to a membrane antigen of human T-cell leukaemia virus (HTLV-I /ATLV)-infected cell lines from a systemic lupus erythematosus (SLE) patient: serological analyses for HTLV-I infections in SLE patients. Clin Exp Immunol 1985; 62:65.
27. Bailer R, Lazo A, Harisdangkul V, Ehrlich G, Gray L, Whisler R,
et al
. Lack of evidence for human T cell lymphotrophic virus type I or II infection in patients with systemic lupus erythematosus or rheumatoid arthritis. J Rheumatol 1994; 21:2217.
28. Olsen R, Tarr M, Mathes L, Whisler R, Plessis D, Schulz E,
et al.
Serological and virological evidence of human T-lymphotropic virus in systemic lupus erythematosus. Med Microbiol Immun 1987; 176:53-64.
29. Bengtsson A, Blomberg J, Nived O, Pipkorn R, Toth L, Sturfel G. Selective antibody reactivity with peptides from human endogenous retroviruses and nonviral poly (amino acids) in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:1654-1663.
30. Danao T, Reghetti G, Yen-Lieberman B, Starkey C, Wakasugi K, McLean-Johnson W,
et al.
Antibodies to the human T lymphocytotropic type I in systemic lupus erythematosus. Clin Exp Rheumatol 1991; 9:55.
31. Higashi J, Kumagai S, Hatanaka M, Imura H. The presence of antibodies to purified p24 gag protein of HTLV-I in sera of patients with systemic lupus erythematosus (SLE). Virus genes 1992; 6:357-364.
32. Scott T, Goust J, Strange C, Brillman J. SLE, thrombocytopenia, and HTLV-I. The J Rheumatol 1990; 17:1565.
33. Ito H, Harada R, Uchida Y, Odashiro K, Uozumi K, Yasumoto Y,
et al
. Lupus nephritis with adult T cell leukemia. Nephron 1990; 55:325.
34. Iwakura Y, Tosu M, Yoshida E, Takiguchi M, Sato K, Kitajima I,
et al.
Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 1991; 253:1026.
35. Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling Sjögren’s syndrome in HTLV-I tax transgenic mice. Nature 1989; 341:72-74.
36 .Gaspar-Sobrinho F, Souza-Machado A, Santos S, Orge G, Lessa H, Cruz A,
et al.
Clinical and immunological features of patients with atopy and concomitant HTLV-I infection. Braz J Med Biol Res 2010; 43:1167-1172.
37. Kannagi M, Hasegawa A, Kinpara S, Shimizu Y, Takamori A, Utsunomiya A. Double control systems for human T cell leukemia virus type 1 by innate and acquired immunity. Cancer Sci 2011; 102:670-676.
38. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
39 .Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A,
et al
. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35:630-640.
40 .Mellors RC, Mellors JW. Antigen related to mammalian type-C RNA viral p30 proteins is located in renal glomeruli in human systemic lupus erythematosus. PNAS?? 1976; 73:233.
41 . Panem S, Ordóñez NG, Kirstein WH, Katz AI, Spargo BH. C-type virus expression in systemic lupus erythematosus. N Eng J Med 1976; 295:470-475.
42. Bowness P, Davies K, Tosswill J, Bunn C, MacAlpine L, Weber JN,
et al
. Autoimmune disease and HTLV-I infection. Rheumatology 1991; 30:141.
43 . Gourley MF, Kisch WJ, Mojcik CF, King LB, Krieg AM, SteinberG AD. Molecular aspects of systemic lupus erythematosus: murine endogenous retroviral expression. DNA Cell Biol 1992; 11:253-257.
44. Phillips PE, Johnston SL, Runge LA, Moore JL, Poiesz BJ. High IgM antibody to human T-lymphotropic virus type I in systemic lupus erythematosus. J Clin Immunol 1986; 6:234-241.